# JANX catalysts: Janux Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/janx/catalysts

> Janux Therapeutics, Inc. (JANX) has no upcoming catalysts in this calendar. The latest recorded is the JANX011 interim data readout, November 9, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for JANX?

Janux Therapeutics, Inc. (JANX) has no upcoming catalysts in this calendar. The latest recorded is the JANX011 interim data readout, November 9, 2026. Press release filed with the SEC (EX-99): "Initial clinical data from the study will be presented during an investor webcast on November 9, 2026." [Calendar and source filings](https://sec-api.dev/companies/janx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-449790, https://www.sec.gov/Archives/edgar/data/1817713/000119312526449790/janx-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/janx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Janux Therapeutics, Inc. |
| Ticker | JANX (Nasdaq) |
| SEC CIK | 1817713 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/janx |

## Cash runway

Cash $945.7M as of 2026-09-30; quarterly burn $25.2M; about 112.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-449918).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [JANX007 trial start](https://sec-api.dev/pdufa/janx007) | JANX | prostate cancer | completed | "In October 2022, the first patient was dosed with our PSMA-TRACTr (JANX007) in our first-in-human Phase 1 clinical trial in patients with prostate cancer." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817713/000095017025029177/janx-20241231.htm)) |
| Apr 2023 | [JANX008 trial start](https://sec-api.dev/pdufa/janx008) | JANX |  | completed | "The first patient was dosed with JANX008 in April 2023 and in February 2024 we announced positive early data for JANX008 that displayed anti-tumor activity in multiple tumor types with low-grade CRS and predominantly low-grade TRAEs." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817713/000119312526076918/janx-20251231.htm)) |
| February 27, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000095017025029165/janx-ex99_1.htm)) |
| May 8, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/janx-ex99_1.htm)) |
| August 7, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/janx-ex99_1.htm)) |
| November 6, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312525269518/janx-ex99_1.htm)) |
| Feb 2026 | [JANX011 trial start](https://sec-api.dev/pdufa/janx011) | JANX |  | completed | "In February 2026, we initiated a Phase 1 clinical study of our CD19-ARM program (JANX011), which is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JANX011 in healthy volunteers." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1817713/000119312526449918/janx-20260930.htm)) |
| February 26, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526076627/janx-ex99_1.htm)) |
| May 7, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526211964/janx-ex99_1.htm)) |
| August 6, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-ex99_1.htm)) |
| November 5, 2026 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526449790/janx-ex99_1.htm)) |
| November 9, 2026 | [JANX011 interim data readout](https://sec-api.dev/pdufa/janx011) | JANX |  | scheduled | "Initial clinical data from the study will be presented during an investor webcast on November 9, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000119312526449790/janx-ex99_1.htm)) |

## Drugs

- [JANX007](https://sec-api.dev/pdufa/janx007): prostate cancer
- [JANX008](https://sec-api.dev/pdufa/janx008): 
- [JANX011](https://sec-api.dev/pdufa/janx011): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/janx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JANX catalysts: Janux Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/janx/catalysts

```bibtex
@misc{secapidev_companies_janx_catalysts_20261116,
  title        = {JANX catalysts: Janux Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/janx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_janx_catalysts_20261116","title":"JANX catalysts: Janux Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/janx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
